top of page

Search Results

Results found for "assay development"

  • Dr. Hannes Schihada | Dr. GPCR Ecosystem

    My project involved the development of FRET/BRET -based GPCR conformational biosensors, which can be I spent 2 1/2 years in his lab and developed novel conformational sensors for these intriguing receptors

  • University Pricing | Dr. GPCR Ecosystem

    these benefits are designed to enhance your research experience and keep you informed about the latest developments Free Apply as an Instructor Developing Countries Full Premium access for researchers in developing countries Do you offer discounts for students or developing countries? Yes. Members from developing countries can join for $24.99/year.

  • Dr. GPCR Board | Dr. GPCR Ecosystem

    She developed expertise over the past two decades studying structure/function relationships of GPCRs the fundamental knowledge of GPCR biology and for the identification of drug targets and future drug development Manager, where they managed a technical support team providing scientific data analysis and database development contributed analytic support resulting in authorship of numerous scientific publications and new funding, and developed delivered technical presentations and software demonstrations to prospective customers worldwide, and developed

  • Dr. Nicola J. Smith | Dr. GPCR Ecosystem

    Together with Irina Kufareva , UCSD, her team developed a novel approach to identifying ligands for orphan GPCRs by developing a powerful new computational tool for identifying ā€˜surrogate’ ligands (borrowed

  • Murat Tunaboylu & Ben Holland | Dr. GPCR Ecosystem

    Mid-career, he has worked in finance and developed high-frequency trading systems. early-stage medical device start-up and in 5 years was responsible for project R&D and managing a focused development

  • Masha Niv: Bitter Taste Receptors and the Drug Discovery Blind Spot | Dr. GPCR Ecosystem

    The conversation also covers what happens when taste pharmacology intersects with drug development - ABOUT THE GUEST Masha Niv is associate professor and vice dean of research and development at the Hebrew Niv's lab developed a machine learning predictor trained on intensely bitter compounds that can flag bitterness risk from chemical structure alone, early in the development pipeline. Niv's lab is developing a recommendation system - trained on known receptor-ligand pairs and the structural

  • Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem

    insightful experiences in academic, hospital, and industry labs, I decided to pursue a role in business development intersection of science and business, which includes target selection, preclinical strategy and business development to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development understand how the principles of receptor allosterism and functional selectivity can be leveraged in the development

  • Exploring Career Paths in GPCR Research with Dr. Jacek Mokrosiński | Dr. GPCR Ecosystem

    mispronunciations, cultural differences, and the importance of a multidisciplinary approach in drug development discussed their research interests, particularly in the field of GPCR, and the importance of method development discussed their professional backgrounds, highlighting the benefits of a multidisciplinary approach in drug development They also highlighted the importance of method development, integrity, and honesty in scientific research

  • Anything BUT GPCRs with Dr. Mikel Garcia-Marcos | Dr. GPCR Ecosystem

    and experimental systems (purified proteins, cultured cells, model organisms) in combination with the development Our ongoing efforts have direct implications in cancer, embryonic development defects, and neurological

  • Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    discussed the importance of hiring based on differentiation, impact, and interest, the need for workforce development will share notes about PRISM and presentability with Arthur. - Arthur will share the story of PRISM's development Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, significance of fundamental discoveries, the role of biotech, and the need for efficiency and process development They also discussed the disruption within the pharmaceutical sector, the importance of workforce development

  • Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    discussed the importance of hiring based on differentiation, impact, and interest, the need for workforce development will share notes about PRISM and presentability with Arthur. - Arthur will share the story of PRISM's development Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, significance of fundamental discoveries, the role of biotech, and the need for efficiency and process development They also discussed the disruption within the pharmaceutical sector, the importance of workforce development

  • You never know where your GPCR takes you with Dr. Brian Hudson | Dr. GPCR Ecosystem

    He has more than 20 years of experience in GPCR, primarily focused on drug discovery and developing new

  • Dr. Claudia StƤubert | Dr. GPCR Ecosystem

    They also explored the possibility of developing an ecosystem for the GPCR University. Developing a Research Ecosystem at GPCR University Yamina and Claudia discussed developing an ecosystem

  • Robert Laprairie | Dr. GPCR Ecosystem

    Robert Laprairie is an Associate Professor and the Saskatchewan Research Chair in Drug Discovery and Development

  • Dr. Nicolas Gilles | Dr. GPCR Ecosystem

    properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic development

  • Terry Hebert: How Cellular Background and Localization Influence GPCR Function | Dr. GPCR Ecosystem

    His lab develops BRET- and FRET-based biosensors that produce different conformational outputs depending His research centers on GPCR signaling networks, biosensor development, and the role of cellular context His lab develops resonance energy transfer-based biosensors and applies them in induced pluripotent stem Hebert's lab developed caged ligands that cross the plasma membrane and are uncaged intracellularly,

  • Empowering Drug Discovery for the GPCR Community with Dr. Justin English | Dr. GPCR Ecosystem

    His lab focuses on developing and innovating technologies to solve broad questions in pharmacology, with

  • Annette Gilchrist: Native Cell Systems, Biased Agonism, and the Pharmacogenomics Gap | Dr. GPCR Ecosystem

    academia, she co-founded two GPCR-focused biotechs with Heidi Hamm - CUE Biotech and Caden Biosciences - developing as a discipline shaped how she has thought about the relationship between target validation and drug development The peptides she developed - 11 amino acids rather than 55, which created their own detection challenges argument Biologics have a substantially higher success rate than small molecules moving through the drug development therapeutics an underexplored area - particularly for orphan GPCRs, where compounds are already being developed

  • From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Ecosystem

    Yekkirala shares the pivotal moments that transformed him from a curious PhD student into a GPCR drug developer scientists interested in translational innovation Biotech investors and strategic leaders seeking new drug development

  • Dr. Josh Pottel | Dr. GPCR Ecosystem

    (MFI): a reliable, self-sustaining computational chemistry service provider, developing its own software

  • Dr. Neil Grimsey | Dr. GPCR Ecosystem

    We have developed an array of fluorescent biosensors to map kinase activity in living cells and are exploring

  • GPCRs and the Science Behind Pain and Recovery with Dr. Alex Serafini | Dr. GPCR Ecosystem

    Pivoting: Redefining the Pain Research Playbook Looking ahead, Serafini’s vision is bold: build a lab that develops He aspires to become a physician-scientist, with a focus on translational in vitro and in vivo model development Other academic interests of his include studying pharmaceutical finance & healthcare administration and developing

  • Dr. Shivani Sachdev | Dr. GPCR Ecosystem

    Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors

  • GPCR location matters with Dr. Gabriele Kockelkoren | Dr. GPCR Ecosystem

    Alice Ting developing programmable receptors for molecular sensing and controlling cellular behaviour

  • Dr. Yamina Berchiche | Dr. GPCR Ecosystem

    She developed expertise over the past two decades studying structure/function relationships of GPCRs

  • The Practical Assessment of Signaling Bias | Dr. GPCR Ecosystem

    Kenakin , a leading expert in pharmacology, as he unpacks the fascinating world of signaling bias in drug development effects. šŸ—£ļø Interactive Q&A : The discussion wraps up with an insightful Q&A, tackling real-world drug development Understanding these shifts can revolutionize drug development! The talk explores how to navigate this crucial gap. šŸ“Œ The Future of Drug Development šŸš€ šŸ”¹ By integrating

  • Vaithish Velazhahan | Dr. GPCR Ecosystem

    He has developed novel tools and methodologies to study fungal GPCRs which allowed the determination

  • The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi | Dr. GPCR Ecosystem

    She is an internationally recognized biophysicist for her contributions in developing constrained molecular

  • Dr. Adriano Marchese | Dr. GPCR Ecosystem

    The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic development

  • Dr. Tobi Langenhan | Dr. GPCR Ecosystem

    deciphering of cellular and organ functions, which require individual adhesion GPCRs, and extends to the development

bottom of page